Non-ST Elevation Myocardial Infarction (nSTEMI)
13
0
1
3
Key Insights
Highlights
Success Rate
60% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
15.4%
2 terminated out of 13 trials
60.0%
-26.5% vs benchmark
23%
3 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (13)
Danish Trial of Beta Blocker Treatment After Myocardial Infarction Without Reduced Ejection Fraction
Prevention of Acute Kidney Injury in Patients With NSTEMI
Antiplatelet Effects of Tirofiban vs. Cangrelor N-STEMI Patients Undergoing Percutaneous Coronary Intervention
The Role of Cardiovascular Magnetic Resonance in Patients With Non-ST- Elevation- Myocardial Infarction
Prehospital Risk Stratification in Acute Coronary Syndromes
Beta Blocker De-prescription Following Coronary Artery Bypass Graft Surgery (BEEFBURGER Trial).
Systemic, Pancoronary and Local Coronary Vulnerability
Risk-score Based ICU Triage
EKG Criteria and Identification of Acute Coronary Occlusion
Vitamin D Deficiency Treatment Outcomes After Non-ST-Segment Elevation Myocardial Infarction
A Trial on the Role of Community Pharmacist in Improving Adherence and Clinical Outcomes in Post-Infarction
Coronary Angioplasty in Octogenarians With Emergent Coronary Syndromes
The Role of Alcohol Consumption in the Aetiology of Different Cardiovascular Disease Phenotypes: a CALIBER Study